Dr. Pere Santamaria, researcher at the University of Calgary and IDIBAPS, coordinates a study published in Nature that provides a new approach to understand and treat autoimmune diseases without compromising the entire immune system. Researchers have discovered a novel cellular mechanism that regulates autoimmune response and a new class of drugs that that harnesses this mechanism to treat various autoimmune diseases. The study conducted in animal models, shows for the first time that autoreactive T-cells, that protect the body against specific autoimmune diseases, can be expanded in vivo in an efficient and reproducible way.
Dr. Pere Santamaria, Professor at the Cumming School of Medicine at the University of Calgary (Canada) and head of the IDIBAPS group Pathogenesis and treatment of autoimmunity, leads the study. The Type 1 Diabetes group, from Department of Physiology and Immunology at the University of Barcelona and led by Dr. Thomas Stratmann, and other researchers from Canada and the US, have also participated.
Autoimmune diseases such as type 1 diabetes, multiple sclerosis or rheumatoid arthritis, are the result of a malfunction of the body’s immune system. In these diseases T lymphocytes, cells, that coordinate the immune response against viruses and bacteria, attack the body’s own cells instead of protecting them, damaging the target organ. To treat the disease, defective cells must be eliminated, but current drugs do not have mechanisms to distinguish them from normal cells. Drugs used to treat these autoimmune diseases also suppress normal immunity, thereby leaving theindividual susceptible to other illnesses.
In the study published in Nature, researchers have discovered that the administration of a novel type of nanoparticles, coated with protein targets directed to T-cells responsible of autoimmune diseases, allows reprogramming them into regulatory T cells and the selective removal of the disease. This happens through a new cellular mechanism that regulates the immune response.
Research has been conducted in animal models of several autoimmune diseases. By this approach glucose blood levels have been restored in mice with type 1 diabetes, motor function has been addressed in mice with a disease similar to multiple sclerosis, and the structure and function of joints have been restored in arthritic mice.
“This discovery is important because now we know how to stop autoimmune diseases in a highly specific manner without compromising immunity in general,” explains Dr. Santamaria. “The mechanism we have discovered and the nanodrugs acting on it has the potential to revolutionize the standard of care for more than 80 autoimmune diseases affecting people,” he adds.
Article reference:
Expanding antigen-specific regulatory networks to treat autoimmunity.
Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, Tsai S, Wang J, Garabatos N, Izquierdo C, Agrawal S, Keough MB, Yong VW, James E, Moore A, Yang Y, Stratmann T, Serra P, Santamaria P.
Nature. 2016 Feb 17. doi: 10.1038/nature16962.
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Investigadores del Cima Universidad de Navarra constatan que la combin...
